EBV vac: New Safe Vaccine for Prevention of Epstein-Barr Virus Infections

Professor Ritter and his co-workers from the Division of Virology, University Hospital of the RWTH Aachen, created a new recombinant Epstein-Barr Virus (EBV)

which has lost the ability to enter the state of latent persistency after infecting host cells. The mutant virus only causes a self-limited infection and is unable to immortalize B-lymphocytes following Infection. Having lost the oncogenic potential of wild type EBV it fulfils the prerequisite for a live vaccine. The inventors generated a mutant virus allowing expression of lytic genes, but preventing the expression of EBV encoded genes essential for the establishment of viral latency. Mutant virus infected B-lymphocytes died after the productive phase.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 0

Contact
Dipl.-Ing. Alfred Schillert

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

Alle Nachrichten aus der Kategorie: Technology Offerings

Zurück zur Startseite

Kommentare (0)

Schreib Kommentar

Neueste Beiträge

An artificial cell on a chip

Researchers at the University of Basel have developed a precisely controllable system for mimicking biochemical reaction cascades in cells. Using microfluidic technology, they produce miniature polymeric reaction containers equipped with…

Specific and rapid expansion of blood vessels

Nature Communications: KIT researchers identify a new mechanism to control endothelial cell size and arterial caliber – basis for better treatment of heart infarct and stroke. Upon a heart infarct…

Climate change drives plants to extinction in the Black Forest in Germany

Climate change is leaving its mark on the bog complexes of the German Black Forest. Due to rising temperatures and longer dry periods, two plant species have already gone extinct…

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close